Infliximab is approved for the treatment of a variety of chronic inflammatory and autoimmune conditions. It is commonly used in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It is often prescribed when patients do not respond adequately to conventional therapies. In many cases, infliximab is used in combination with other medications, such as methotrexate, to improve treatment outcomes and control disease progression.

Infliximab works by targeting and neutralizing tumor necrosis factor-alpha (TNF-alpha), a protein that plays a central role in inflammation. In autoimmune diseases, TNF-alpha is produced in excess, leading to chronic inflammation and tissue damage. By binding to TNF-alpha, infliximab prevents it from interacting with its receptors, thereby reducing inflammation and immune system overactivity. This helps relieve symptoms, promote healing of affected tissues, and slow disease progression.

Infliximab is administered as an intravenous infusion in a clinical setting under the supervision of a healthcare professional. The dosing schedule typically involves an initial loading phase followed by maintenance infusions every several weeks, depending on the condition being treated. Each infusion may take a few hours, and patients are monitored during and after the procedure for any reactions. The exact schedule and dose are tailored to the patient’s condition and response to therapy.

Infliximab is generally effective, but it can cause side effects due to its impact on the immune system. Common side effects include infusion-related reactions such as fever, chills, itching, or rash. Patients may also experience fatigue, headache, abdominal pain, or upper respiratory infections. Because infliximab suppresses immune function, it can increase the risk of infections, including serious ones such as tuberculosis. In rare cases, it may be associated with liver problems, blood disorders, or certain types of cancer. Regular monitoring is important to ensure safety.

Infliximab should not be used in patients with severe infections, such as active tuberculosis or sepsis. Screening for latent infections is essential before starting treatment. Caution is required in patients with heart failure, liver disease, or a history of certain cancers. It is also important to evaluate vaccination status, as live vaccines should generally be avoided during treatment. Infliximab is not recommended during pregnancy unless clearly necessary, and patients should discuss risks and benefits with their healthcare provider.

Infliximab has significantly improved the treatment of chronic inflammatory and autoimmune diseases by targeting a key driver of inflammation. Its ability to provide long-term disease control and improve quality of life has made it a cornerstone in modern therapy. However, due to its immunosuppressive effects, careful monitoring and medical supervision are essential. With appropriate use, infliximab continues to offer meaningful benefits for patients managing complex inflammatory conditions.

Infliximab is used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis.

It works by blocking TNF-alpha, a protein responsible for inflammation, thereby reducing immune system activity and relieving symptoms.

Infliximab is given as an intravenous infusion in a healthcare setting, typically at regular intervals after an initial loading phase.

Common side effects include infusion reactions, infections, fatigue, headache, and abdominal discomfort. These are usually manageable with proper care and monitoring.

Yes, because it suppresses the immune system, it can increase the risk of infections, including serious ones like tuberculosis. Screening and monitoring are essential.

No, infliximab is a biologic therapy, specifically a monoclonal antibody, not a chemotherapy drug.

Patients with active infections, severe heart failure, or known hypersensitivity to the drug should avoid infliximab unless advised otherwise by a doctor.